|
| Tuesday, December 20, 2016 |
|
|
Anticancer Agent Treakisym Approved in Japan for Additional Indication as First-Line Treatment for Low-Grade B-Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma |
| Eisai Co., Ltd. announced today that the anticancer agent TREAKISYM (generic name: bendamustine hydrochloride) has been approved in Japan for an additional indication as first-line treatment for low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma (MCL). more info >> |
|
| Friday, November 18, 2016 |
|
|
U.S. FDA Grants Fast Track Designation for the Development of Eisai's Bace Inhibitor E2609 for Early Alzheimer's Disease |
| Eisai Co., Ltd. announced today that the U.S. FDA has granted Fast Track designation for the development of the beta secretase cleaving enzyme (BACE) inhibitor E2609 which was discovered by Eisai and is being jointly developed by Eisai and Biogen Inc. more info >> |
|
| Friday, November 4, 2016 |
|
|
U.K. NICE Recommends Anticancer Agent Halaven as Treatment for Advanced Breast Cancer |
| Eisai Co., announced today that its in-house developed anticancer agent Halaven has been recommended by the U.K. National Institute for Health and Clinical Excellence (NICE) as a treatment for patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for advanced disease in NICE's Final Appraisal Determination (FAD). more info >> |
|
| Monday, October 31, 2016 |
|
|
Enrollment Commences in Phase III Clinical Study of Eisai's BACE Inhibitor E2609 in Early Alzheimer's Disease |
| Eisai Co., Ltd. announced today that enrollment has commenced in MISSION AD, a Phase III clinical program of the beta secretase cleaving enzyme (BACE) inhibitor E2609 in patients with early Alzheimer's disease in the United States. more info >> |
|
| Thursday, October 13, 2016 |
|
|
Eisai to Officially Launch "Chocola BB Rich Ceramide" in Stores Nationwide |
| Eisai Co., Ltd. announced today that it will launch its first food with function claims Chocola BB Rich Ceramide in drugstores, pharmacies and convenience stores throughout Japan on Monday, October 17. more info >> |
|
| Wednesday, October 12, 2016 |
|
|
Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 |
| Eisai Co., Ltd. announced today that a presentation on the results of a Phase Ib clinical study of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in combination with the anti-PD-1 antibody pembrolizumab developed by Merck & Co., Inc., known as MSD outside the United States and Canada, in patients with selected solid tumors was given at the European Society for Medical Oncology (ESMO) Congress held from October 7 to 11. more info >> |
|
| Tuesday, October 4, 2016 |
|
|
Exclusive Licensing Agreement for In-house Developed Monoclonal Antibody Farletuzumab in Latin America Concluded with Eurofarma Laboratorios S.A. |
| Eisai Co., Ltd. announced today that its research subsidiary Morphotek, Inc. has signed an exclusive licensing agreement with Eurofarma Laboratorios S.A. to develop and commercialize the monoclonal antibody farletuzumab as a potential anticancer agent in Latin America. more info >> |
|
|
Launch of Uritos Tablets for Overactive Bladder in Thailand |
| Eisai Co., Ltd. and KYORIN Holdings, Inc. announced today that Eisai's Thai subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched Uritos Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, in Thailand. more info >> |
|
|
BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched BELVIQ XR 20mg tablets, a new once-daily formulation of BELVIQ (generic name: lorcaserin hydrochloride) for chronic weight management in the United States. more info >> |
|
| Friday, September 30, 2016 |
|
|
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced ienttoday the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma. more info >> |
|
|
|
